XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

September 30, 2026

NYSE: $BMY

PRINCETON, N.J.–(BUSINESS WIRE) September 30, 2026 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic…

Source: Read More

FDA Acceptance

$BMY, Bristol Myers Squibb, Camzyos, Cardiomyopathy, FDA Approval, Hypertrophic, mavacamten, Obstructive, oHCM, pediatric, Symptomatic

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

30 DAY

60 DAY

90 DAY

120 DAY

UNLIMITED

Get FREE Biotech Stock Catalyst Reports

Email